Results 161 to 170 of about 7,041 (257)

Real‐World Effectiveness and Treatment Patterns of Tirzepatide in a Large UK Digital Health Cohort

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Tirzepatide has demonstrated substantial weight‐loss efficacy in clinical trials, but real‐world evidence from routine digital prescribing remains limited. Methods We conducted a retrospective cohort study of adults initiating tirzepatide for obesity via a UK digital prescribing service between March 2024 and July 2025. Linked order‐
Onayomi Rosenior‐Patten, Zoe Lees, Rebecca Rowe, Safia Hussain, Ehtasham Ahmad, Edward Brooke, Sophie Dix, Catriona Maybury   +7 more
wiley   +1 more source

In vitro dissolution and release kinetics of multisource ciprofloxacin 500 mg tablets in West Gondar, Ethiopia: Implications for interchangeability and regulatory oversight. [PDF]

PLoS One
Haile TD, Ashenef A, Demeke CA, Anagaw YK, Mekonen AW, Worku MC, Beirhun AM, Mekasha YT, Feleke MG.   +8 more
europepmc   +1 more source

Baseline Computed Tomography Coronary Angiography and Polygenic Risk Profiles in Adults With Type 2 Diabetes: A Cross‐Sectional Analysis From the VOLTAIRE Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To characterise baseline clinical, anatomical, and genetic cardiovascular risk profiles in participants enrolled in the VOLTAIRE (Evaluation of Polygenic Scores and CT Imaging in Risk Factor Modification in Patients with Type 2 Diabetes) study and examine concordance across these domains. Methods This analysis included adults with T2D who
Ruofei (Trophy) Chen, Adam J. Nelson, Sophia Zoungas, Robyn A. Clark, Sean Tan, Esther F. Davis, Melissa C. Southey, Andrew Lin, Giuseppe Di Giovanni, Masashi Fujino, Jennifer Wong, Robert L. O'Reilly, Jacqueline S. Dron, Stephen J. Nicholls   +13 more
wiley   +1 more source

Analysis of the Effect of the Tablet Matrix on the Polymorphism of Ibuprofen, Naproxen, and Naproxen Sodium in Commercially Available Pharmaceutical Formulations. [PDF]

Methods Protoc
Leyk E, Środa M, Maślanka G, Nowaczyk P, Orzołek A, Grodzka H, Kurek A, Knut O, Michalak J, Płachciak J, Plenis A.   +10 more
europepmc   +1 more source

Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early‐Phase Clinical Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The management of the disease of obesity has been transformed by incretin‐based therapies; however, additional and alternative therapeutic strategies are needed to address its biological complexity. This narrative review examines the physiology of amylin and the emerging role of amylin‐based therapies in obesity management.
Abdulhameed Alhazmi, Carel W. le Roux
wiley   +1 more source

Manufacturing Supply Chains and Imports in the ADHD Drug Shortage.

JAMA Health Forum
Currie J, Malinovskaya A.
europepmc   +1 more source

Development of a Taste-Masked, Dose-Flexible, Multiparticulate Pediatric Dosage Form: Case Study of Crizotinib, a Challenging Pediatric Formulation. [PDF]

Pharmaceut Med
Bartlett JA, Culver N, Santangelo M, Prpich A, Long E, Sagawa K, Shanker R, Xu H, Wilner K.   +8 more
europepmc   +1 more source

Early Weight Regain After GLP‐1 Receptor Agonist Discontinuation: Mechanisms and Implications for Treatment De‐Escalation Strategies

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have transformed the pharmacological management of obesity, producing substantial and sustained weight loss during active treatment. However, discontinuation of therapy is frequently followed by significant weight regain, raising important questions regarding the durability of treatment ...
M. A. Damhof, F. H. van Bruggen, E. N. van Roon   +2 more
wiley   +1 more source

Review of Structural Modification and Development of Novel Tramadol Derivatives. [PDF]

Molecules
Wang N, Zhou X, Wang J, Sun L, Liu B, Yin L.   +5 more
europepmc   +1 more source

Insulin, Semaglutide and Dapagliflozin in Adults With Type 1 Diabetes: Design and Methods of Triple Therapy for Type 1 Diabetes (TTT1)—An International Phase 3 Clinical Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Attaining target glycaemia can be a challenge in Type 1 Diabetes (T1D) due to insulin‐induced weight gain. Adjunct therapy with modern glucose‐lowering agents developed for type 2 diabetes (T2D) has great potential but may be insufficiently efficacious and carries risks of hypoglycaemia and ketosis.
Joseph G. Timmons, Husam Ghanim, James G. Boyle, Nicola Greenlaw, Ajay Chaudhuri, Manav A. Batra, Robert S. Lindsay, Lisa Jolly, Caroline Bonner, Alex McConnachie, John R. Petrie, Paresh Dandona   +11 more
wiley   +1 more source